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Antagonists of various hormonal steroids are 
important not only as molecular probes to 
delineate adreno-corticoid action but also as 
potential drugs in syndromes of hormone excess 
and in control of fertility. Although various levels 
of hormone antagonism are possible, the major 
emphasis of this workshop was to review recent ad- 
vances in the chemical synthesis and biological ac- 
tivity of molecules capable of acting at the level of 
the specific receptor in the cell. Other means of an- 
tagonism were reviewed as well in order to provide 
an opportunity for interaction between experts in 
different fields. 
hemiketal isomer in which the A ring of the steroid 
is drawn toward the &face as a result of epoxide 
formation. The only common feature between al- 
dosterone and its antagonists pironolactone and 
canrenone is the 4-en-3-one composition and the 
conformation of their A-rings; the absence of 
hydrogen donating groups in the D-ring may ac- 
count for the antagonist activity of the latter two 
molecules. 
Dr Sonino (Padova) reviewed the inhibition of 
steroid hormone synthesis and clinical manage- 
ment of hormone excess syndromes, primarily 
Cushing’s disease, by aminogluthemide, mety- 
rapone and o’ p ’ DDD, where side effects pose 
serious problems. Immunization of rats with cor- 
ticosterone was attempted by Dr Vecsei (Heidel- 
berg) with some success but it appears some way 
off before it can be exploited as a specific means 
to antagonize hormone activity. 
18-Deoxyaldosterone possesses one third the 
binding affinity of aldosterone for the cytoplasmic 
receptor but exhibits a 2: 1 antagonist o agonist 
ratio, despite close resemblance in the shape of 
rings A, B, C, and E. 
Dexamethasone oxetanone is a potent glucocor- 
ticoid antagonist but its A, B and C rings are near- 
ly identical to that of dexamethasone, the agonist. 
However, although both molecules can accept a 
hydrogen bond at 0(20), only the agonist can 
donate two hydrogen bonds in the D-ring. 
Dr Duax (Buffalo) analysed X-ray crystal con- 
formations of a number of molecules to identify 
the structural features associated with receptor 
binding and biological response. Although 
aldosterone has 7 possible structural isomers, the 
most stable form remains the 18,11-acetal-20,18- 
Collectively, high affinity binding to the 
mineralocorticoid receptor (MR) appears to be 
related to a complementary fit between amino 
acids of the receptor site and a flat 4-en-3-one A 
ring; the glucocorticoid receptor (GR) appears to 
prefer a 4-en-3-one A ring that is bowed towards 
the a-face. Specific interactions between the 
steroid B, C and D rings and the receptor appear 
to play at best a minor role in receptor binding but 
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are the most important factor in determining 
agonist vs antagonist behaviour subsequent to 
binding. 
Dr Wambach (Cologne) explored structure- 
activity correlation of newly synthesized 
aldosterone antagonists. Replacement of the 
17-spirolactone ring by a 17cu-hydroxypropyl or a 
17&hydroxyl group led to a loss of affinity for the 
receptor without a loss of antialdosterone action in 
vivo. C6/C7 unsaturated compounds, and 
methylation of the D-ring of spirolactone reduced 
activity both in vivo and in vitro. Substitution of 
the I;r,-thioacetyl group in the &position (pro- 
renone) increased activity in vivo as well as in 
vitro. Two derivatives of spirorenone were 3-8 
times more active than spirolactone in vivo but 
their affinity for the MR was only slightly in- 
creased. If spirolactone was taken as lOO%, the 
relative affinity of 6,%, 7,&, IS,&, l@?-dimethylene 
derivatives of spironolactone for MR ranges from 
O.l-200%. 
progesterone) antagonize aldosterone binding to 
the putative MR in the intestinal mucosa. A close 
similarity in the hydrodynamic properties of GR 
and MR was noted. In the fish, cortisol an- 
tagonizes corticosterone binding to CR whereas 
progesterone and aldosterone show no GR affini- 
ty. There are clear hydrodynamic differences in the 
GR from these two sources (avian vs fish). He sug- 
gested that in the bird, the same macromolecule 
adopts a conformation of either GR or MR, 
depending upon the agonist. In the vertebrate, 
however, GR appears to be an ancestral whose MR 
functions evolved through interaction with the 
tetrapod hormone aldosterone. 
The clinical usefulness of spironolactone is 
limited by its antitestosterone properties, as evi- 
dent by binding to the androgen receptor (AR) in 
prostate cytosol. Although the affinities for the 
MR and AR do not correlate derivatives with 
higher affinity for AR than spironolactone are 
more potent than this molecule for testosterone 
receptors in vitro. 
Dr Ramsay (Sheffield) pointed out that new 
spirolactones are clearly needed for treatment of 
essential hypertension and oedematous tates since 
molecules now available provoke gynaecomastia 
and other side effects. In vitro binding assays of 
newly synthesized derivatives did not provide a 
reliable means of predicting their potency in man, 
and could not distinguish agonists from an- 
tagonists. Prediction of renal potency in man was 
improved when lactones were used in binding 
studies in place of carboxylic acids. Furthermore, 
metabolic transformation of spirolactones was ex- 
tensive, complex and widely different between 
various species. It was suggested that newly syn- 
thesized materials should be tested for binding to 
the MR in vitro and then tried clinically at the 
earliest possible stage. 
Dr Teutsch (Romainville) reported a major 
breakthrough in the search for anti-glucocorticoids 
by a method developed at Roussel (Patent 
2213272). This epoxide pathway consists of epox- 
idation with hexafluoroacetone hydroperoxide, or 
30% hydrogen peroxide-hexachloroacetone in the 
1 l/3 position of 19-nor-steroids followed by a con- 
jugate opening of the epoxide by lithium cuprate to 
the 1 lo-substituted compound as the sole reaction 
product. This is by far the most convenient method 
for introducing almost any organic group to yield 
1 l&substituted 4,9-estradienes and 1,3,5(10)- 
estratrienes. 1 lb-substitution with vinylic or 
aromatic radicals led to very high binding affinities 
for both the GR and the progestin receptor (PR), 
both of which possess a large hydrophobic pocket 
of lo-12 A able to accommodate substituents as 
large as a phenyl ring. Furthermore, the presence 
of a hydrogen bond donor in the steroid clearly did 
not appear necessary for binding to the receptor. It 
was established that mere C-11 substitution can 
transform an agonist into an antagonist. Thus, the 
1 l&vinyl derivative (RU 42744) is a full agonist 
but the 1 I,&-4-dimethylaminophenyl compound 
(RU 38486) is a pure antagonist, both in the 
glucocorticoid and the progestational sense. 
Aliphatic substitutions in the 1lP position are com- 
patible with GR binding while considerably 
decreasing affinity for PR. However, complete 
dissociation of GR from PR has not yet been possi- 
ble. Notwithstanding, a major breakthrough in the 
anti-glucocorticoid field has been attained. 
Dr Sandor (Montreal) attempted a comparison Dr Philibert (Romainville) reviewed for the first 
of the binding properties of GR and MR from time the biological activity of RU 38486 [17fi- 
various species. In the domestic duck and chicken, hydroxy-1 lo-{4-dimethylaminophenyl)- 17& 1 -pro- 
the most powerful GR agonists (corticosterone, pynyl)-estra-4,9-diene-3-one], shown below. Its 
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affinity for both rabbit uterine PR and rat thymus 
GR was 5 times that of progesterone and 3 times 
that of dexamethasone. In thymocytes, it fully an- 
tagonized the thymolytic effects of dexamethasone 
in concentrations lower than that of the agonist on 
total organ weight and RNA synthesis. In vivo, a 
single oral dose of 10 mg/kg totally inhibited in- 
duction of rat liver tryptophan pyrrolase, tyrosine 
transaminase and glycogen in response to 10 /rg/kg 
dexamethasone, and also blocked the action of the 
glucocorticoid on ACTH secretion and diuresis. In 
all bioassays it was totally devoid of any agonist 
activity up to 1O-6 M in vitro and 100 mg/kg in 
vivo. 
RU 38486 
RU 38486 is also a potent antiprogestative with 
inhibition of endometrial proliferation in rabbits 
and antinidatory and abortive properties in the rat. 
Antiandrogenic property on total rat prostate mass 
was noted at dose level of 30 mg/kg, orally. 
Clinically, it has already undergone successful 
trials in the treatment of Cushing’s syndrome, and 
in termination of unwanted pregnancy, both 
without side effects. Thus, a revolutionary new 
material is clearly available for the first time. 
Dr Agarwal (Paris) pointed out that RU 38486 
reversed the protective effect of dexamethasone 
against endotoxin shock and also sensitized mice to 
a sublethal dose of the toxin. Again, no agonist ac- 
tivity of RU 38486 was noted, although the time 
course of action suggested that GR may not be 
directly involved under these conditions. 
Dr Berry (Austin) described the mechanism of 
action of the glucocorticoid antagonising factor 
(GAF) which is released from the macrophages of 
animals given bacterial endotoxins that are well 
known to oppose hormone induction of liver en- 
zymes in vivo. GAF did not interfere with the for- 
mation or activation of the hormone-receptor 
complex. However, GAF interferes with the 
transcription of the gene that codes for liver 
phosphoenolpyruvate carboxykinase in some 
unknown way. Being an antagonist of endogenous 
origin, GAF may find an eventual clinical applica- 
tion but large scale production and purification are 
still a way off. 
Dr Moudgil (Rochester) reported that the bind- 
ing of steroid-receptor complexes to isolated 
nuclei, DNA-cellulose and ATP-Sepharose was 
abolished if the complex is incubated at 23°C in 
the presence of molybdate, tungstate or vanadate. 
Pyridoxal 5 ‘-phosphate, aurintricarboxylic acid, 
heparin, o-phenanthroline and rifamycin AF/103 
completely blocked the binding of the receptor to 
the acceptor either by inhibition of receptor activa- 
tion or by decreasing the affinity of the receptor 
for the acceptor. The mechanism of action of these 
inhibitors appears to be different and may be ex- 
ploited in receptor purification. 
Dr Sato (Osaka) reported the presence of small 
M, dialysable materials that inhibit rat liver GR ac- 
tivation in vitro. This was not true of rat uterine 
estrogen receptor (ER). Dr Kalimi (Richmond) 
could remove factors of this type by dextran char- 
coal leading to diminished dexamethasone bind- 
ing. His factor is not dialysable, thermolabile, had 
a Stoke’s radius of 4-5 nm, and was inactivated by 
RNase and dithiothreitol. Calcium and magnesium 
ions, too, accelerated GR inactivation whereas 
EDTA and EGTA stabilized receptor binding. 
Glucorticoid antagonism was also exhibited by 
several intracellular enzymes (phospholipases, pro- 
teases, alkaline phosphatases). The role of all these 
substances, that occur naturally in vivo, needs 
careful scrutiny to delineate hormone action. 
It is now well accepted that the receptor for all 
classes of steroid hormones is heterogeneous. This 
heterogeneity manifests itself in various ways 
depending upon the tissue, the steroid, and the 
resin used for receptor fractionation. Despite this 
obvious polymorphism, almost invariably it is 
assumed that a ‘classical’ receptor must be hidden 
somewhere in the midst of all this multiplicity of 
steroid-bound receptor peaks. Instead of just 
shrugging off this mass of biochemical data, Dr 
Agarwal (Paris) attempted a physiological inter- 
pretation of receptor heterogeneity. To date, it has 
not been possible to establish whether these multi- 
ple peaks are indeed different proteins or modified 
versions of a more fundamental, basic unit. It is 
however inconceivable that the genetic repertory 
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should possess sufficient flexibility to transcribe 
separate receptors for all possible synthetic 
agonists and antagonists that are being made 
available day after day. It is inconceivable, too, 
that all agonists of mineralocorticoids, for exam- 
pie, should exert a physiological action by 
saturating the same site, since deoxycorticosterone 
and its 1%hydroxy derivative possess only a tenth 
of the affinity of aldosterone for MR and are pro- 
duced in only trace amounts in vivo. 
Some of the confusion stems from the fact that 
receptor is quantitated only after it has interacted 
with the hormone. The nature of the native recep- 
tor in vivo appears to be quite different. First, 
receptor stabilisation by steroid hormones is well 
established but formation of this complex, and 
subsequent activation, leads to nuclear transfer. 
Heat activation in vitro has no relevance in vivo 
where all processes are simultaneously occurring at 
37°C or so. Second, adrenalectomy depletes en- 
dogenous hormones but actually increases the 
amount of available receptor in vivo - in con- 
tradiction to the stabilizing role of the hormone in 
vitro. Thus, the inescapable conclusion is that the 
presence of free receptor in cell cytoplasm in vivo 
must be due to mechanisms that cannot be ex- 
plained by observations that have hitherto been 
made in vitro. 
As shown in fig.1 it therefore seems very likely 
that a nascent, proreceptor is consistently present 
in the cytoplasm, is not bound to the steroid, and 
its stability is assured by its association with the 
ribosome after translation of the receptor mRNA. 
As soon as an appropriate ligand is presented to 
this nucleo-protein complex, the receptor protein 
may be freed of its ribosomal support. Rat liver 
GR is known to be associated with RNA and 
RNase A converts it from a heavy 7-8 S to a light 
3-4 S form that is conventionally assayed in vitro. 
Thus, a basic tenet of the model presented here 
is the right conformation conferred upon the 
ribosome-bound proreceptor by the ligand, 
thereby rendering it geometrically disposed for 
post-translational modification by a whole battery 
of ions, chelators, inhibitors and activators (fig. 1). 
The levels of receptor in vivo are regulated by the 
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Fig.1. The Argusoid model. The name Argusoid is derived from the Greek myth of Argus, whose chief role was the 
surveillance and coordination by virtue of 100 eyes, just as the receptor must be sensitive to a myriad cellular demands, 
processes, and modulating factors. 
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amount of the specific ligand and support the 
model here. In addition, the mature holoreceptor 
may be fully active at the level of MTV translation, 
contrary to the classical viewpoint where the 
steroid-receptor complex modulated only gene 
transcription. 
It follows, therefore, that exploitable targets for 
hormone antagonism may be sought at all of the 
levels shown in the model, although such efforts 
are usually limited to steroid-receptor-acceptor 
association in vitro. 
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